A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT05466643

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05466643
Other papers using this trial's data
  • Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs Diabetes & metabolism journal, 2026-09 DOI, PubMed 41397686, PMC13561644 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05466643. Randomized; quadruple masking; primary purpose treatment. Start 2023-03-17 (actual); primary completion 2024-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus
Acronym
ENHANCE-I
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
DWP16001 0.3mg
Intervention (Drug)
DWP16001 Placebo
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct05466643
Content hash
211cdba47cb39d247af2248f4699efa9e89b5a95a54654386cc82648049488d1